Patient-Level Data: A New Level of Analysis

The new kid on the block is patient-level data. Unlike physician-level data that describes the wholesale activity of Dr. John Smith as writing say 50 scripts of Lipitor, patient-level data zooms in on the patients of Dr. John Smith and specifies patient by patient who actually gets Lipitor.

Online and Offline Professional and Consumer Marketing

Attending conferences like the recent Pharmaceutical Marketing Global Summit provides tidbits of information about how pharma marketing practices need to evolve. Although the advice from one expert often conflicts with that of another, and sometimes the advice is self-serving, some suggestions seem to ring true and have universal support.

Has DTC Spending Peaked?

There are powerful lobbyists, including employers, insurers, AARP, and Public Citizen, with an anti-DTC agenda in Washington. The criticism takes many forms - increases in drug prices, increase in inappropriate prescribing, etc. Republicans have gained control, but some committee chairs are DTC critics.

PhRMA Code Helps Re-define Roles of Medical Affairs and Marketing

A power shift from marketing to medical affairs may be the result of the new PhRMA Code on Interactions with Healthcare Professionals as well as the final Compliance Program Guidance for Pharmaceutical Manufacturers issued on April 28, 2003, by the HHS Office of Inspector General (OIG).

Out-of-the-Box Marketing: Will It Work for Pharma?

This presentation put out-of-the-box marketing ideas such as Permission Marketing into the context of pharmaceutical promotions. Dr. Vanderveer -- the presenter -- posed important questions that pharmaceutical market researchers must ask themselves, especially in light of two looming pharmaceutical marketing crises: Decreasing ROI and Fewer Blockbuster Drugs.

Consumer Use of the Internet for Health: Whose Numbers Do You Believe?

Whose numbers do you believe? Which study should you quote when making a case to pharmaceutical product managers to integrate the Internet into their marketing strategy? This article provides some useful analysis of the various studies and will help you determine which reigns supreme.

Developing Win-Win Key Opinion Leader Relationships

This article features results from research by Cutting Edge Information, a pharmaceutical business intelligence firm in Durham, North Carolina. Cutting Edge studied winning practices in thought leader management and has worked closely with more than a dozen KOL management executives from industry leaders, such as Pfizer, AstraZeneca and GlaxoSmithKline.

Ethical Online Practices Build Consumer Trust

Although pharmaceutical firms claim they are not required to comply with regulations enacted under the Health Insurance Portability and Accountability Act of 1996, using HIPAA as a model for online policy may help drug companies improve their public images, build trust with consumers and, ultimately, sell more products.

OpEd: More Permission, More Data, Better Marketing?

What's the connection between the effectiveness of DTC advertising, patient-level data vs. physician-level data, and out-of-the-box marketing? Adoption of these new techniques and data sources by pharmaceutical marketers depends on good education, vendor cooperation, and success stories to prove that the effort is worth it

PhRMA Code Helps Re-define Roles of Medical Affairs and Marketing

A power shift from marketing to medical affairs may be the result of the new PhRMA Code on Interactions with Healthcare Professionals as well as the final Compliance Program Guidance for Pharmaceutical Manufacturers issued on April 28, 2003, by the HHS Office of Inspector General (OIG).
- Advertisement -